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Types of stem cells
- Embryonic stem cells: pluripotent, inner mass cells (blastocyst)
- Adult Stem cellsmultipotent, different tissues:
- Neural stem cells
- Hematopoietic stem cells
- Mesenchymal stem cells (MSC)
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Discussion
Safety and feasibility have been reported in the vast majority of the studies. The engraftment of
these cells in the injured tissue are not significant. However, the way that they act is via stimulate
the endogenous cells, and contribute to neuroprotection. There are numerous reasons for optimism
concerning the use of MSC for neural repair. The next step in this therapies is to verify if they can
revert the diseases.
Introduction
Stem cells field has their origin in the 60s when they was discover. But it was not until 90s when a revolution occur: isolation of stem cells and a cultivation of them was achieve. From this moment, the
progenitor cell have been as the great hope of the new century therapeutics. Studies report some extraordinary information and the idea of treat neurological diseases with stem cells appear. Due to the
burden of some neurological diseases, such as Parkinson, Multiple Sclerosis or Amyotrophic lateral Sclerosis diseases, the necessity of new therapies have increased. Nevertheless, the issue that hinder some
therapies, like stem cell therapy is the lack of agreement about how is the most suitable way to proceed in the extraction, culture, way of administration and type of stem cell that is suitable to use. Here it is
shown one process of this therapy and also, some recent progress.
1-ASPIRATION 2-ISOLATION
Percoll gradient :1100g, 30 
min. Collect interphase and 
wash with *PBS
Remove anticoagulant 
medium 900g, 15 min
1
2
Density gradient centrifugation in 
Ficoll-Plaque
Layering onto a limphoprep
density gradient
4-HARVEST
*DMEM medium:
• 10 % fetal bovine serum or not
• 1 % penicillin/streptomycin
3-4 passages
80 % confluence
0,25 % trypsin/EDTA
Iliac crest
3- CULTURE and EXPANSION
Quantity:
• 1-2x106 cells/kg or
• 3-5x107cells/patient
Resuspended and washed in *DPBS
 Remove *FBS
Cryopreservation in:
• 4,5% human albumin solution
• 10% dimethyl sulfoxide
5-CHARACTERISATION
Flow cytometry:
• Presence of Surface markers:
CD73,CD90,CD105,CD29,CD44,CD66
• Absence of:
CD34,CD45,CD14,CD31
Viability:
• Tripan blue
• Propidium iodide
Karyotyping 
Endotoxin levels
6-ADMINISTRATION
Intravenously Intrathecally
Subventricular zone 
Aspiration of 
10-200ml/patient
Immunomodulation
Anti-inflammatory
Low probability of tumour
Genetic modification
Migration to sites of injury
Avoid ethical problems
Characteristics of MSC
Plasticity
3h with basal medium 
without serum  washed 
with PBS Resuspended
in autologous 
cerebrospinal fluid
There is no effective treatment!
Alternatives needed.
Conclusion
According to the studies, there is a lack of common protocols of doing this kind of therapy. In fact, in
the summary of the method described above, it can be seen different kinds of protocols with the same
objective. Nevertheless, results are positive and the best choice of stem cells to use seem to be the
MSC. However, more preclinical studies should done in order to resolve some issues about MSC
such as the effect of released factors or the plasticity of the cells. By the other hand, it is not yet
completely known the way by MSC can integrate into the damaged central nervous system.
Neurodegenerative diseases
- Parkinson disease
- Multiple sclerosis disease
- Huntington disease
- Amyotrophic lateral sclerosis
Methodology
*DMEM: Dulbecco’s Modified Eagle Medium; FBS: Fetal Bovine Serum; DPBS: Dulbecco’s Phosphate Buffered Saline; EDTA: Ethylenediaminetetraacetric acid; PBS: Phosphate Buffered Saline
